CN110105453A - 运铁蛋白-肿瘤抑素融合蛋白质及其生成和使用方法 - Google Patents

运铁蛋白-肿瘤抑素融合蛋白质及其生成和使用方法 Download PDF

Info

Publication number
CN110105453A
CN110105453A CN201910156923.9A CN201910156923A CN110105453A CN 110105453 A CN110105453 A CN 110105453A CN 201910156923 A CN201910156923 A CN 201910156923A CN 110105453 A CN110105453 A CN 110105453A
Authority
CN
China
Prior art keywords
transferrin
tumorstatin
protein
cells
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910156923.9A
Other languages
English (en)
Chinese (zh)
Inventor
U·B·科姆佩拉
R·I·沙因曼
P·泰亚吉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado System
Original Assignee
University of Colorado System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado System filed Critical University of Colorado System
Publication of CN110105453A publication Critical patent/CN110105453A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201910156923.9A 2011-08-17 2012-08-15 运铁蛋白-肿瘤抑素融合蛋白质及其生成和使用方法 Pending CN110105453A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161524508P 2011-08-17 2011-08-17
US61/524,508 2011-08-17
CN201280051256.4A CN103998470A (zh) 2011-08-17 2012-08-15 运铁蛋白-肿瘤抑素融合蛋白质及其生成和使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280051256.4A Division CN103998470A (zh) 2011-08-17 2012-08-15 运铁蛋白-肿瘤抑素融合蛋白质及其生成和使用方法

Publications (1)

Publication Number Publication Date
CN110105453A true CN110105453A (zh) 2019-08-09

Family

ID=47715692

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910156923.9A Pending CN110105453A (zh) 2011-08-17 2012-08-15 运铁蛋白-肿瘤抑素融合蛋白质及其生成和使用方法
CN201280051256.4A Pending CN103998470A (zh) 2011-08-17 2012-08-15 运铁蛋白-肿瘤抑素融合蛋白质及其生成和使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201280051256.4A Pending CN103998470A (zh) 2011-08-17 2012-08-15 运铁蛋白-肿瘤抑素融合蛋白质及其生成和使用方法

Country Status (15)

Country Link
US (1) US9290562B2 (https=)
EP (1) EP2744831B1 (https=)
JP (1) JP6073888B2 (https=)
CN (2) CN110105453A (https=)
AU (1) AU2012296588B2 (https=)
BR (1) BR112014008680A2 (https=)
CA (1) CA2849015C (https=)
DK (1) DK2744831T3 (https=)
ES (1) ES2659161T3 (https=)
NO (1) NO2820418T3 (https=)
PL (1) PL2744831T3 (https=)
PT (1) PT2744831T (https=)
SI (1) SI2744831T1 (https=)
TR (1) TR201802686T4 (https=)
WO (1) WO2013025846A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2995626B1 (en) * 2013-05-06 2018-07-11 China Pharmaceutical University Bifunctional fusion proteins to inhibit angiogenesis in tumour microenvironment and to activate adaptive immune responses and the genes and uses thereof
US20160137717A1 (en) * 2013-06-20 2016-05-19 Gabriela Burian Use of a vegf antagonist in treating choroidal neovascularisation
US11058750B2 (en) 2015-12-03 2021-07-13 Mor Research Applications Ltd. Compositions and methods for treatment of ocular diseases
KR101818151B1 (ko) 2016-03-25 2018-01-16 한국과학기술원 트렌스페린을 포함하는 허혈성망막병증 예방 및 치료용 조성물
CN109053899B (zh) * 2017-12-22 2021-11-16 湖南远泰生物技术有限公司 一种含人转铁蛋白抗原表位序列的嵌合体抗原受体

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060172941A1 (en) * 2004-10-14 2006-08-03 Luca Rastelli Anti-angiogenic peptides and methods of use thereof
CN101070349A (zh) * 2007-05-22 2007-11-14 山西康宝生物制品股份有限公司 具有选择性杀伤肿瘤新生血管内皮细胞作用的融合蛋白与应用
CN101092452A (zh) * 2007-05-23 2007-12-26 哈尔滨医科大学 肿瘤抑素抗血管生成小分子多肽、融合蛋白及两者制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672683A (en) 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US20050192242A1 (en) 1995-10-11 2005-09-01 Neal Zane C. Therapeutic fusion protein transgenes
CA2331332A1 (en) * 1998-06-17 1999-12-23 Raghuram Kalluri Anti-angiogenic proteins and methods of use thereof
EP1244701A1 (en) 1999-12-23 2002-10-02 Human Genome Sciences, Inc. Transferrin polynucleotides, polypeptides, and antibodies
AU2002323501C1 (en) 2001-08-30 2010-04-29 Biorexis Technology, Inc Modified transferrin fusion proteins
US8129504B2 (en) * 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
WO2003066824A2 (en) * 2002-02-07 2003-08-14 Aventis Behring Gmbh Albumin-fused kunitz domain peptides
WO2005034877A2 (en) 2003-10-10 2005-04-21 University Of Southern California G-csf transferrin fusion proteins
US20050266067A1 (en) * 2004-03-02 2005-12-01 Shiladitya Sengupta Nanocell drug delivery system
WO2006049983A2 (en) 2004-10-27 2006-05-11 Biorexis Pharmaceutical Corporation Peptide yy modified transferrin fusion proteins
CA2606989A1 (en) * 2005-04-29 2006-11-09 Research Development Foundation Vascular targeting of ocular neovascularization
WO2007087689A1 (en) 2006-02-03 2007-08-09 Crc For Asthma And Airways Ltd A method of modulating cellular activity and agents for use therein
WO2009086132A2 (en) * 2007-12-20 2009-07-09 University Of Southern California Design of spacers to increase the expression of recombinant fusion proteins
AU2012222833B2 (en) 2011-03-03 2017-03-16 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060172941A1 (en) * 2004-10-14 2006-08-03 Luca Rastelli Anti-angiogenic peptides and methods of use thereof
CN101070349A (zh) * 2007-05-22 2007-11-14 山西康宝生物制品股份有限公司 具有选择性杀伤肿瘤新生血管内皮细胞作用的融合蛋白与应用
CN101092452A (zh) * 2007-05-23 2007-12-26 哈尔滨医科大学 肿瘤抑素抗血管生成小分子多肽、融合蛋白及两者制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KRYSTEN M FARJO等: "The potential of nanomedicine therapies to treat neovascular Disease in the retina", 《JOURNAL OF ANGIOGENESIS RESEARCH》 *

Also Published As

Publication number Publication date
DK2744831T3 (en) 2018-03-05
JP6073888B2 (ja) 2017-02-01
EP2744831A2 (en) 2014-06-25
NO2820418T3 (https=) 2018-05-05
EP2744831A4 (en) 2015-03-11
AU2012296588A1 (en) 2014-04-03
JP2014526890A (ja) 2014-10-09
US9290562B2 (en) 2016-03-22
BR112014008680A2 (pt) 2017-06-13
CN103998470A (zh) 2014-08-20
US20140179612A1 (en) 2014-06-26
SI2744831T1 (en) 2018-04-30
CA2849015C (en) 2017-08-08
WO2013025846A2 (en) 2013-02-21
CA2849015A1 (en) 2013-02-21
EP2744831B1 (en) 2017-12-06
TR201802686T4 (tr) 2018-03-21
PT2744831T (pt) 2018-03-05
WO2013025846A3 (en) 2013-05-02
PL2744831T3 (pl) 2018-05-30
AU2012296588B2 (en) 2017-07-27
ES2659161T3 (es) 2018-03-14

Similar Documents

Publication Publication Date Title
Liu et al. Penetratin, a potentially powerful absorption enhancer for noninvasive intraocular drug delivery
CN110036024B (zh) 肌肉性能改善化合物
CN101687927B (zh) 针对g蛋白偶联的受体（gpcr）的抗体
CN106255699B (zh) 细胞穿透肽和使用其输送生物活性物质的方法
DK2744831T3 (en) TRANSFERRIN-TUMSTATIN-FUSION PROTEIN AND PROCEDURES FOR PREPARING AND USING THE SAME
Johnen et al. Antiangiogenic and Neurogenic Activities of Sleeping Beauty‐Mediated PEDF‐Transfected RPE Cells In Vitro and In Vivo
CN103930439A (zh) 基因工程生长因子变异体
US9469679B2 (en) Neurturin molecules
JP2024543158A (ja) 多重特異性リガンド結合分子及びその用途
JP6440107B2 (ja) 細胞シートの製造方法、組成物、細胞培養補助剤、及び細胞培養方法
CN121399149A (zh) 具有c端氨基酸添加物的突变型wnt7蛋白
JP7560185B2 (ja) 補体経路阻害剤及び血管新生阻害剤を含む融合タンパク質並びにその使用
EP2774935B1 (en) Improved neurturin molecules
CN120476152A (zh) C5/vegf双特异性结合分子
EP3096769A1 (en) Therapeutic use of vegfr-3 ligands
JP2026500221A (ja) 治療薬または診断薬の局所的ローディングのための細胞外マトリックス結合化合物
CN119522235A (zh) 用于选择性淋巴管刺激的vegf-c突变蛋白
HK40110067A (zh) 血管生成抑制剂缀合的抗c3b抗体或抗c5抗体及其用途
Kumar-singh Platform for Rapid Delivery of Biologics and Drugs to Ocular Cells and Tissues Following Combat Associated Trauma

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20190809